Find Clinical Trial

Prevention of cerebrovascular and cardiovascular Events of ischaemic origin with teRutroban in patients with a history oF ischaemic strOke or tRansient ischaeMic attack. The PERFORM Study. An international, randomised, double-blind, two parallel group study comparing terutroban 30 mg o.d. versus aspirin 100 mg o.d. administered orally for a 3-year mean duration (event driven trial). – PERFORM


← Back
Study Phase

Phase 3

Therapeutic Area

Cardiovascular Diseases

IndicationStroke
SponsorInstitut de Recherches Internationales Servier (I.R.I.S)
Active substance/
Medical device

TERUTROBAN,
S018886

Active Substance CodeS018886
Protocol CodeCL3-18886-012
EudraCT Code2005-003700-10
ISRCTN CodeISRCTN66157730


Documents and links

Results summary READ MORE
Scientific publication READ MORE




Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



© 2022 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
Accessibility